Keyphrases
Oral Formulation
100%
Early Alzheimer's Disease
100%
Alzheimer's Disease Patient
100%
GMP Production
100%
Alzheimer's Disease
100%
Toxicology
100%
Tolerability
66%
Clinical Drugs
66%
Clinical Trials
66%
Cytokine Production
66%
Drug Candidates
66%
Disease Progression
66%
Drug Substance
66%
FDA Guidance
66%
Recovery Phase
33%
Toxicokinetics
33%
Toxicological Safety
33%
Oral Treatment
33%
Drug Quality
33%
Toxicology Studies
33%
Long-term Administration
33%
Cytokine Dysregulation
33%
Safety Pharmacology
33%
Phase 2a Clinical Trial
33%
Public Health Risk
33%
Therapeutic Approaches
33%
CNS Disorders
33%
Activated Glia
33%
Hemorrhagic Stroke
33%
Global Public Health
33%
Pharmacodynamics
33%
Physical Properties
33%
Pathophysiology
33%
Disease Areas
33%
Preclinical Safety
33%
Alzheimer's Dementia
33%
Oral Administration
33%
Technical Barriers
33%
Anti-inflammatory Cytokines
33%
Related Dementia
33%
Pharmacokinetics
33%
Inflammatory Cytokines
33%
Diversified Portfolio
33%
Small Molecules
33%
Synaptic Dysfunction
33%
Neurodegenerative Diseases
33%
Overproduction
33%
Dysregulated
33%
Penetrant
33%
Successful Outcome
33%
Toxicity Study
33%
Dementia
33%
Effective Therapy
33%
Phase II Trial
33%
Cognitive Decline
33%
First-in-human
33%
Clinical Development
33%
Neurodegeneration
33%
Critical Care Medicine
33%
Phase 1 Clinical Trial
33%
Neuroinflammation
33%
Patient Compliance
33%
Pharmacological Profile
33%
Population Aging
33%
New Therapeutic Strategies
33%
World Population
33%
Pharmacological Functions
33%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Formulation
100%
Guanosine Phosphate
100%
Alzheimer's Disease
100%
Toxicology
100%
Cytokine
66%
Clinical Study
50%
Clinical Trial
50%
Tolerability
33%
Disease Exacerbation
33%
Diseases
33%
Drug Quality
16%
Preclinical Study
16%
Anti-Inflammatory Drug
16%
Safety Pharmacology
16%
Pharmacodynamics
16%
Nerve Degeneration
16%
Brain Hemorrhage
16%
Nervous System Inflammation
16%
Pathophysiology
16%
Degenerative Disease
16%
Toxicokinetics
16%
Pharmacokinetics
16%